Approval of audited consolidated and standalone financial results for the year ended March 31, 2026 along with recommendation of final dividend
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Windlas Biotech Limited reported annual revenue of Rs. 9,040.89 million for FY2026, up 19% from Rs. 7,598.78 million in FY2025. Profit after tax grew 9% to Rs. 664.56 million from Rs. 609.94 million. Basic EPS increased to Rs. 31.60 from Rs. 29.19. The Board recommended a dividend of Rs. 6.30 per share (126% on face value of Rs. 5). EBITDA margin remained stable at around 13% with minimal change year-over-year. Auditors issued unmodified (clean) opinions on both standalone and consolidated financial statements. Key notes include a share buyback of 470,000 shares at Rs. 1,000 each and dissolution of subsidiary Windlas Inc., USA effective March 31, 2026.
Positive signals for shareholders with revenue and profit growth, clean audit opinion, and dividend recommendation. However, growth rates are moderate (19% revenue, 9% PAT) rather than exceptional, and EBITDA margin showed negligible change.